Unknown PHASE2 INTERVENTIONAL 1-arm NCT04656002

As a Second-line Treatment for Metastatic Gastric Adenocarcinoma Patients, the Safety and Effective of Vactosertib Administration in Combination With Paclitaxel+Ramucirumab is Evaluated, and a Phase 2a Clinical Trial to Biomarkers

Sponsor: Samsung Medical Center

Interventions Vactosertib

Updated 5 times since 2021 Last updated: Jun 13, 2022 Started: Oct 31, 2022 Primary completion: Dec 31, 2023 Completion: Dec 31, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04656002, this PHASE2 trial focuses on Gastric Cancer and remains ongoing. Sponsored by Samsung Medical Center, it has been updated 5 times since 2022, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Jan 2025 — Present [monthly]

Unknown PHASE2

Status: Not Yet Recruiting → Unknown
Sep 2024 — Jan 2025 [monthly]

Not Yet Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE2
Jul 2022 — Jul 2024 [monthly]

Not Yet Recruiting PHASE2
Jan 2021 — Jul 2022 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Samsung Medical Center

Data source: Samsung Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.